RespireRx Pharmaceuticals Announces Preliminary Top-Line Analysis of Data from Duke University Phase 2A Clinical Trial of CX1739
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement